The continuous glucose monitor (CGM) market

CGMs are wearable devices that continuously monitor glucose levels in people with diabetes. They are often used by people with type 1 diabetes who require insulin therapy, but they are also increasingly being used by people with type 2 diabetes.

Here are some key trends and factors driving growth in the CGM market:

1. Increasing prevalence of diabetes: The number of people with diabetes is increasing globally, particularly in developing countries. This is driving demand for better and more convenient diabetes management tools, including CGMs.
2. Technological advancements: Advances in CGM technology, such as improved accuracy and better integration with insulin pumps and other diabetes management tools, are making CGMs more effective and convenient for patients.
3. Rising healthcare costs: Healthcare costs are rising globally, and CGMs can help reduce healthcare costs by improving diabetes management and reducing the risk of diabetes-related complications.
4. Increased patient awareness: Patients are becoming more aware of the benefits of CGMs, particularly in terms of improving diabetes management and reducing the risk of hypoglycemia and hyperglycemia.
5. Growing reimbursement: Reimbursement policies for CGMs are improving in many countries, making CGMs more accessible to patients.

Some key players in the CGM market include Abbott, Dexcom, Medtronic, and Senseonics. These companies are investing in research and development to improve CGM technology and expand their product offerings. They are also partnering with healthcare providers and payers to increase patient access to CGMs. Overall, the CGM market is expected to continue to grow in the coming years, driven by these and other factors.

Abbott is a global healthcare company that operates in several different areas of healthcare, including medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. Abbott’s business model is centered around creating and selling innovative healthcare products and services to improve the health and wellbeing of people around the world. Here are some key elements of Abbott’s business model:

1. Diversified product portfolio: Abbott’s product portfolio spans several different areas of healthcare, including medical devices (such as cardiovascular devices and diabetes care products), diagnostics (such as COVID-19 tests and molecular diagnostic tests), nutrition (such as infant formula and adult nutrition products), and branded generic pharmaceuticals (such as pain management and gastrointestinal products). This diversification helps Abbott manage risk and capture opportunities across different segments of the healthcare market.
2. Research and development: Abbott invests heavily in research and development to develop new and innovative products that can address unmet medical needs. In 2020, Abbott invested approximately $2.3 billion in research and development. This investment has helped Abbott bring many new products to market, such as the FreeStyle Libre system for continuous glucose monitoring in diabetes patients.
3. Focus on emerging markets: Abbott has a strong presence in emerging markets such as China, India, and Latin America. These markets offer significant growth opportunities due to their large and growing populations and increasing demand for healthcare products and services. Abbott has adapted its business model to these markets by developing products specifically for these markets and by establishing local manufacturing and distribution capabilities.
4. Partnerships and acquisitions: Abbott has formed partnerships with other companies and made strategic acquisitions to expand its product portfolio and geographic reach. For example, in 2020, Abbott acquired Tendyne Holdings, Inc., a company that develops minimally invasive therapies for advanced heart failure. This acquisition helped Abbott expand its presence in the cardiovascular device market.
5. Customer-centric approach: Abbott places a strong emphasis on understanding the needs of its customers and developing products and services that meet those needs. This customer-centric approach has helped Abbott build strong relationships with healthcare providers, patients, and other stakeholders in the healthcare industry.

Overall, Abbott’s business model is focused on creating and selling innovative healthcare products and services that address unmet medical needs, while also managing risk and capturing growth opportunities across different segments of the healthcare market.

Abbott has a strong portfolio of continuous glucose monitoring (CGM) products, which are designed to help people with diabetes better manage their blood glucose levels. Here are some of the key products in Abbott’s CGM portfolio:

1. FreeStyle Libre: The FreeStyle Libre is a flash glucose monitoring system that allows users to monitor their glucose levels continuously without the need for fingerstick tests. The system consists of a small sensor that is worn on the back of the upper arm, and a handheld reader or smartphone app that displays glucose data. The FreeStyle Libre also provides users with trend information and alerts for high and low glucose levels.
2. FreeStyle Libre 2: The FreeStyle Libre 2 is an enhanced version of the original FreeStyle Libre system. It provides users with real-time glucose readings, as well as customizable high and low glucose alerts. The FreeStyle Libre 2 also features a built-in Bluetooth transmitter, which allows users to share their glucose data with healthcare providers and caregivers.
3. FreeStyle Libre 3: The FreeStyle Libre 3 is the latest iteration of the FreeStyle Libre system. It features a smaller, more discreet sensor, and provides users with continuous glucose monitoring without the need for a handheld reader. Instead, the FreeStyle Libre 3 sends glucose data directly to a smartphone app, making it more convenient and user-friendly.
4. FreeStyle Navigator II: The FreeStyle Navigator II is a continuous glucose monitoring system designed for people with type 1 diabetes. It provides users with real-time glucose data, trend information, and alarms for high and low glucose levels. The FreeStyle Navigator II also features a user-friendly interface and is designed to be worn for up to 14 days.

Overall, Abbott’s CGM portfolio is designed to provide people with diabetes with accurate and convenient glucose monitoring solutions. The company is committed to investing in research and development to improve its CGM technology and expand its product offerings, and to partnering with healthcare providers and payers to increase patient access to its products.